In fact, analysts may now be wondering if the roughly $54 billion estimate they were modeling needs to come down not up.
#Salesx forecast update
However, with Wall Street already unconvinced about the $60 billion target, this latest update provided analysts with little reason not to be more confident in their own, lower, estimate. That's still well above analyst estimates of roughly $54 billion. On the post-earning call, management said they see Pharmaceutical sales in 2025 closer to $57 billion than the $60 billion forecast two years ago. We're leaning toward the second reason: Management's 2025 Pharmaceutical sales target because J & J's results would have exceeded estimates even without strong vaccine sales.
First, Covid vaccine-related sales, a less sustainable source of revenue, were so strong that they made the magnitude of the overall quarterly revenue beat seem less impressive to some investors. Bottom line Given J & J's strong Q1 results and rosy full-year outlook, we're surprised to see the stock sell-off so harshly, trading below $160 per share at the lows of Tuesday's session. On an operational basis, earnings per share (EPS) increased 3% year over year. Adjusted diluted earnings came in at $2.68 per share, a solid beat versus the $2.50 per share estimate. On an adjusted operational basis, which excludes the impact of acquisitions and divestitures as well as currency fluctuations, sales rose 9% year over year. J & J's first-quarter sales of $24.75 billion exceeded the Refinitv consensus estimate of $23.67 billion. Shares of the Dow component and Club holding should not be losing 2.5% on these kinds of results. Johnson & Johnson (JNJ) before-the-bell Tuesday reported a strong first quarter, with sales up more than 5.5% and earnings eking out an annual increase. Personal Loans for 670 Credit Score or Lower Personal Loans for 580 Credit Score or Lower Best Debt Consolidation Loans for Bad Credit
0 kommentar(er)
